ELEVATE-TN
Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL
- NCT02475681 ↗
- Active, not recruiting
- Acerta Pharma BV
- Deep
We haven't built an HCP commentary report on ELEVATE-TN (acalabrutinib plus obinutuzumab; acalabrutinib in treatment-naive chronic lymphocytic leukemia) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Questions raised in the commentary
Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice.
The commentary discusses ElevateTN’s frontline CLL design, including acalabrutinib alone or with obinutuzumab versus chlorambucil and obinutuzumab, the eligible population, crossover, and progression-free survival as the primary endpoint. Discussion also covers longer-term follow-up and the comparison of acalabrutinib monotherapy with the antibody combination. The commentary raises whether obinutuzumab adds enough value to justify its use, alongside concerns about added toxicity, infusion-related effects, and cost, and whether further follow-up is needed to clarify who benefits from the antibody.
Indexed commentary on ELEVATE-TN so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 77 | |
| Podcasts | 58 | |
| X threads | 11 | |
| Bluesky threads | 2 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination With Chlorambucil, Acalabrutinib (ACP-196) in Combination With Obinutuzumab, and Acalabrutinib Monotherapy in Subjects With Previously Untreated CLL
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Acalabrutinib; Obinutuzumab; Chlorambucil
- Arms
- Arm A - Obinutuzumab in Combination with Chlorambucil · Active comparator
- Arm B - Acalabrutinib in Combination with Obinutuzumab · Experimental
- Arm C - Acalabrutinib Monotherapy · Experimental
- Enrollment
- 535
- Primary outcomes
- Progression-free Survival by IRC (Independent Review Committee) Assessment in Arm A Compared to Arm B
- Sponsor
- Acerta Pharma BV
- Start
- Jun 26, 2015
- Primary completion
- Feb 8, 2019
- Results posted
- Yes
- Registry record
- NCT02475681 · updated Aug 25, 2026
Publications
linked from the registry- Sharman JP, Egyed M, Jurczak W, Skarbnik A, Patel K, Flinn IW, Kamdar M, Munir T, Walewska R, Hughes M, Fogliatto LM, Herishanu Y, Banerji V, Follows G, Walker P, Ghia P, Janssens A, Byrd JC, Ferrant E, Ferrajoli A, Wierda WG, Wachira CW, Suterwala BT, Miranda P, Munugalavadla V, Wun CC, Woyach JA. Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood. 2025 Sep 11;146(11):1276-1285. doi: 10.1182/blood.2024024476. PubMed 40198878
- Kittai AS, Allan JN, James D, Bridge H, Miranda M, Yong ASM, Fam F, Roos J, Shetty V, Skarbnik A, Davids MS. An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL. Blood Adv. 2024 Jun 11;8(11):2861-2869. doi: 10.1182/bloodadvances.2023012142. PubMed 38598745
- Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2. PubMed 32305093